MTD 240-670A User Manual download pdf

2014

Threshold Pharm

(THLD

NASDAQ)

Current Recommendation

Outperform

Prior Recommendation

N/A

Date of Last Change

04/27/2014

Current Price (08/01/14)

$4.13

Twelve

Month Target Price

$9.50

OUTLOOK

SUMMARY DATA

Risk Level

Above Avg.,

Type of Stock

N/A

Industry Med-

Biomed/Gene

Zacks Rank in Industry

N/A

Threshold is a late development

stage

biopharmaceutical company focused on developing

hypoxia targeted cancer therapy.

The Company s

lead prodrug candidate TH

302 is in a series of

clinical trials including two Phase III clinical trials for

soft tissue sarcoma and pancreatic cancer

respe

ctively.

We model TH

302 to be approved by the FDA in

2016 for soft tissue sarcoma. The Company will be

cash flow positive in 2018. Balance sheet remains

strong.

We rate Threshold Outperform based on its strong

fundamentals.

Week

High

$5.72

Week Low

$3.53

One

Year Return (%)

26.82

Beta

2.28

Average Daily Volume (sh)

387,762

Shares Outstanding (mil)

Market Capitalization ($mil)

$245

Short Interest Ratio (days)

13.89

Institutional Ownership (%)

Insider Ownership

(%)

Annual Cash Dividend

$0.00

Dividend Yield (%)

0.00

Yr. Historical Growth Rates

Sales (%)

N/A

Earnings Per Share (%)

N/A

Dividend (%)

N/A

P/E using TTM EPS

N/A

P/E using 2014 Estimate

N/A

P/E using 2015 Estimate

N/A

Zacks Rank

N/A

ZACKS ESTIMATES

Revenue

(in millions of $)

Year

(Mar)

(Jun)

(Sep)

(Dec)

2013

3.2

12.5 A

2014

.7 A

3.9 E

4.0 E

15.2 E

2015

18.5

2016

27.0

Earnings per Share

(EPS is operating earnings before non recurring items)

Year

(Mar)

(Jun)

(Sep)

(Dec)

2013

$0.11

$0.12

$0.08

$0.13

$0.45

2014

$0.14

$0.12 A

-$0.14 E

-$0.15 E

-$0.55 E

2015

$0.57

2016

$0.54

Zacks Projected EPS Growth Rate

Next 5 Years %

N/A

Small-Cap Research

scr.zacks.com

10 S. Riverside Plaza, Chicago, IL 60606

August 4

, 2014

Grant Zeng, CFA

312

265

9466

[email protected]

THLD: exited 2Q14 with strong balance

sheet, updated data from 2014 ASCO

meeting

Outperform

1 2 3 4 5 6 ... 25 26

Summary of Contents

Page 1 - Threshold Pharm

Page 2 - WHAT S NEW

Zacks Investment Research Page 10 scr.zacks.com

Page 3

Zacks Investment Research Page 11 scr.zacks.com

Page 4

Zacks Investment Research Page 12 scr.zacks.com

Page 5

Zacks Investment Research Page 13 scr.zacks.com

Page 6

Zacks Investment Research Page 14 scr.zacks.com

Page 7 - OVERVIEW

Zacks Investment Research Page 15 scr.zacks.com

Page 8 - VESTMENT THESIS

Zacks Investment Research Page 16 scr.zacks.com

Page 9

Zacks Investment Research Page 17 scr.zacks.com

Page 10

Zacks Investment Research Page 18 scr.zacks.com

Page 11

Zacks Investment Research Page 19 scr.zacks.com

Page 12

Zacks Investment Research Page 2 scr.zacks.com

Page 13

Zacks Investment Research Page 20 scr.zacks.com

Page 14

Zacks Investment Research Page 21 scr.zacks.com

Page 15

Zacks Investment Research Page 22 scr.zacks.com

Page 16

Zacks Investment Research Page 23 scr.zacks.com

Page 17

Page 18

Page 19

Zacks Investment Research Page 26 scr.zacks.com

Page 20

Zacks Investment Research Page 3 scr.zacks.com

Page 21

Zacks Investment Research Page 4 scr.zacks.com

Page 22

Zacks Investment Research Page 5 scr.zacks.com

Page 23

Zacks Investment Research Page 6 scr.zacks.com

Page 24

Zacks Investment Research Page 7 scr.zacks.com

Page 25 - DISCLOSURES

Zacks Investment Research Page 8 scr.zacks.com

Page 26

Zacks Investment Research Page 9 scr.zacks.com

Comments to this Manuals

No comments

MTD 240-670A User Manual

Browse online or download User Manual for Pet care MTD 240-670A. this Report (PDF 1.02 MB)

Summary of Contents

Comments to this Manuals